#161804

KPAR-G12C Cell Line

Cat. #161804

KPAR-G12C Cell Line

Cat. #: 161804

Organism: Mouse

Tissue: Lung

Model: Mutant

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Julian Downward, Pablo Romero-Clavijo, Miriam Molina-Arcas

Institute: The Francis-Crick Institute

Primary Citation: Boumelha et al. 2022. Cancer Research. 82(19):3435-3448. PMID: 35930804.

Tool Details
Handling
Related Tools
References
Documentation

Tool Details

*FOR RESEARCH USE ONLY

  • Name: KPAR-G12C Cell Line
  • Alternate name:  
  • Organism: Mouse
  • Tissue: Lung
  • Donor:  
  • Model: Mutant
  • Model description: A derivative from the KPAR cells, where the mutation Asp in position 12 from KRAS (G12D) was mutated to Cys (G12C) using prime editing.
  • Crispr: No
  • Products or characteristics of interest:  
  • Description: Mouse models of mutant KRAS-driven lung cancer with an elevated tumour mutational burden by expressing the human DNA cytosine deaminase, APOBEC3B, to mimic the mutational signature seen in human lung cancer. The ability of KRAS/KRASG12 inhibitors to cause regression of KRASG12C expressing tumours was markedly potentiated by the adaptive immune system.
  • Production details: A derivative from the KPAR cells, where the mutation Asp in position 12 from KRAS (G12D) was mutated to Cys (G12C) using prime editing.
  • Biosafety level: 1
  • Recommended controls:  

Handling

  • Passage number:  
  • Growth medium: DMEM media supported with 10% FBS, glutamine and penicillin/streptomycin
  • Temperature:  
  • Atmosphere:  
  • Shipping conditions: Dry ice
  • Storage medium:  
  • Storage conditions: Liquid Nitrogen
  • Initial handling information:  
  • Subculture routine:  
  • Cultured in antibiotics: Penicillin, Streptomycin
  • Str profiling:  

Related Tools

  • Related tools:  

References

  • Boumelha et al. 2022. Cancer Research. 82(19):3435-3448. PMID: 35930804.

Documentation